Stockscreener 앱 받기
0.00
100.00%
-9.02
전일 마감가:
$9.02
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$N/A
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$15.94
Range Cancer Therapeutics Etf Stock (CNCR) Company Profile
CNCR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CNCR
Range Cancer Therapeutics Etf
|
0.00 | 0 | 0 | 0 | 0 | 0.00 |
|
VTI
Vanguard Total Stock Market Etf
|
328.86 | 417.53B | 0 | 0 | 0 | 0.00 |
|
SPY
Spdr S P 500 Etf Trust
|
667.79 | 372.57B | 0 | 0 | 0 | 0.00 |
|
IVV
Ishares Core S P 500 Etf
|
671.11 | 253.41B | 0 | 0 | 0 | 0.00 |
|
VB
Vanguard Small Cap Etf
|
254.08 | 160.59B | 0 | 0 | 0 | 0.00 |
|
QQQ
Invesco Qqq Trust Series 1
|
605.49 | 124.43B | 0 | 0 | 0 | 0.00 |
Range Cancer Therapeutics Etf 주식(CNCR)의 최신 뉴스
5 Small-cap Biotech ETFs to Watch in 2025 - Investing News Network
Best Biotech Stocks to Buy in 2025 - The Motley Fool
Unlocking Cures: How AI is Reshaping Cancer Research & Healthcare ETFs? - TradingView
N2OFF Stockholders Approve Merger With Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer - 富途牛牛
Investing in the DNA of Tomorrow: Explore Gene Stocks and Genomics ETFs - Investing News Network
Exploring the SPDR S&P Biotech ETF (XBI) for Biotech Industry Exposure - AInvest
4 Cancer Stocks to Consider in 2025 - The Motley Fool
Range Cancer Therapeutics ETF (NASDAQ: CNCR)Share Price - intelligentinvestor.com.au
When the Price of (CNCR) Talks, People Listen - news.stocktradersdaily.com
ICE to Expand NYSE Index Family With Launch of U.S. Tech Index and Broader Range of NYSE-Listed Indices - The Globe and Mail
The Best Biotech Stocks to Buy - Morningstar
When (CNCR) Moves Investors should Listen - news.stocktradersdaily.com
Percheron Acquires Cancer Therapy Licence - Sharecafe
Where are the Opportunities in (CNCR) - news.stocktradersdaily.com
Caris Life Sciences IPO Prices Above Range to Raise $494 Million - Bloomberg
Guardian Capital Announces June 2025 Cash Distributions for Guardian Capital ETFs - The Globe and Mail
(CNCR) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Vividion Therapeutics and Bayer Further Strengthen Oncology Development Pipeline with Clinical-Stage WRN Inhibitor - Yahoo Finance
This ETF Could Turn $500 Per Month Into a $851,000 Portfolio Paying $30,000 in Annual Dividend Income - The Globe and Mail
Summit stock down after cancer trial data (update) (NASDAQ:SMMT) - Seeking Alpha
Friday's big stock stories: What’s likely to move the market in the next trading session - CNBC
ETF Channel: Range Cancer Therapeutics ETF Implied Analyst Target Price $20.61, Upside 132.35% - AInvest
Trend Tracker for (CNCR) - news.stocktradersdaily.com
Gilead Sciences, Inc. (GILD) and Kite to Present Breakthrough Cancer Therapy Data at 2025 ASCO and EHA - Yahoo Finance
CIBC Asset Management launches three new actively managed CIBC ETFs, expanding its cash management and fixed income ETF suite - The Globe and Mail
Avacta Group Announces Investor Webinar on Latest Cancer Therapy Developments - TipRanks
Weekly ETF Industry Recap: U.S., Europe, and Canada HighlightsMay 5-10, 2025 - Trackinsight
Exchange Traded Concepts to Close and Liquidate the Range Cancer Therapeutics ETF - The Joplin Globe
Learn to Evaluate (CNCR) using the Charts - news.stocktradersdaily.com
Cold Spring Harbor Laboratory’s Ludmila Pollock lauded as fellow of AAAS - TBR News Media
Mythic Therapeutics Presents Preclinical Data Demonstrating Potent Efficacy of MYTX-011 Across a Broad Range of Tumor Xenograft Models Harboring Clinically Relevant Mutations at the American Association for Cancer Research (AACR) Annual Meeting - Yahoo Finance
Long Term Trading Analysis for (CNCR) - news.stocktradersdaily.com
7 Best Pharmaceutical Stocks to Buy for Income | Investing - US News Money
From Panic to Positioning: Top ETFs to Watch After Asia’s Tariff Shock - The Globe and Mail
10 Best Health Care Stocks to Buy for 2025 - US News Money
7 Top Gene-Editing Stocks to Buy | Investing - US News Money
Sellas Life Sciences Advances in Cancer Treatment Development - TipRanks
Buffer ETFs to Consider for Protecting Gains and Limiting Losses - The Globe and Mail
S&P 500 Index Funds Yield Just 1.3%. Consider Buying These 2 Low-Cost Vanguard ETFs to Generate More Passive Income. - The Globe and Mail
Bull or Bear, These 2 ETFs Don’t Care - The Globe and Mail
1 No-Brainer Artificial Intelligence (AI) ETF to Buy With $40 During the Nasdaq Sell-Off - The Globe and Mail
7 Best-Performing Biotech ETFs for March 2025 - NerdWallet
Top ETFs to Invest in Japan - The Globe and Mail
Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025 - Investing News Network
The Unstoppable Momentum in Oncology M&A - Nasdaq
2025 Outlook: Healthcare Technology & Innovation - ETF Trends
The Best Way to Invest in Gold Is... - The Globe and Mail
SELLAS Life Sciences Group, Inc. Secures $25 Million in Registered Direct Offering for Cancer Therapeutics Development - Nasdaq
5 US Longevity and Anti-aging Stocks to Watch in 2025 - Investing News Network
NEW: The Most Popular Sponsored Content of 2024 - Visual Capitalist
Investors Eye Biotech Stocks as Cancer Therapies Take Center Stage in 2025 - baystreet.ca
Range Cancer Therapeutics Etf (CNCR) 재무 분석
Range Cancer Therapeutics Etf (CNCR)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.31%
자본화:
|
볼륨(24시간):